Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The interaction and orientation of Peptide KL4 in model membranes.
Marquardt D, van Oosten B, Dziura M, Long JR, Harroun TA. Marquardt D, et al. Among authors: van oosten b. Biochim Biophys Acta Biomembr. 2022 Jul 1;1864(7):183893. doi: 10.1016/j.bbamem.2022.183893. Epub 2022 Feb 25. Biochim Biophys Acta Biomembr. 2022. PMID: 35219719 Free article.
Lipid bilayer thickness determines cholesterol's location in model membranes.
Marquardt D, Heberle FA, Greathouse DV, Koeppe RE, Standaert RF, Van Oosten BJ, Harroun TA, Kinnun JJ, Williams JA, Wassall SR, Katsaras J. Marquardt D, et al. Soft Matter. 2016 Nov 28;12(47):9417-9428. doi: 10.1039/c6sm01777k. Soft Matter. 2016. PMID: 27801465 Free article.
[Treatment of multiple sclerosis].
Meijs N, De Jong BA, Van Oosten BW, Strijbis EMM. Meijs N, et al. Among authors: van oosten bw. Ned Tijdschr Geneeskd. 2024 May 6;168:D7617. Ned Tijdschr Geneeskd. 2024. PMID: 38747608 Dutch.
Successful treatment of respiratory failure in Hirayama disease.
Sol N, Hartman J, Ten Kate M, van Kempen Z, van der Kooi A, Vandertop P, Tuinman PR, van Oosten B. Sol N, et al. Among authors: van oosten b. Am J Emerg Med. 2024 Feb;76:272.e3-272.e5. doi: 10.1016/j.ajem.2023.11.049. Epub 2023 Dec 2. Am J Emerg Med. 2024. PMID: 38072732 Free article.
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
Toorop AA, van Lierop ZY, Gelissen LM, Hoitsma E, Zeinstra EM, van Rooij LC, van Munster CE, Vennegoor A, Mostert JP, Wokke BH, Kalkers NF, Hoogervorst EL, van Eijk JJ, Roosendaal CM, Kragt JJ, Eurelings M, van Genugten J, Nielsen J, Sinnige L, Kloosterziel ME, Arnoldus EP, van Dijk GW, Bouvy WH, Wessels MH, Boonkamp L, Strijbis EM, van Oosten BW, De Jong BA, Lissenberg-Witte BI, Barkhof F, Moraal B, Teunissen CE, Rispens T, Uitdehaag BM, Killestein J, van Kempen ZL. Toorop AA, et al. Among authors: van oosten bw. J Neurol Neurosurg Psychiatry. 2024 Apr 12;95(5):392-400. doi: 10.1136/jnnp-2023-332119. J Neurol Neurosurg Psychiatry. 2024. PMID: 37963723 Clinical Trial.
88 results